© 1999 Oxford University Press
Article |
Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression
Mayo Clinic Arizona, 13400 East Shea Boulevard, Department of Biochemistry and Molecular Biology, Scottsdale, AZ 85259, USA
Previous cancer chemoprevention studies have demonstrated that NSAIDs can be effective in suppressing the development of intestinal tumors. To further explore this issue, we performed cross-over chemoprevention studies using the drug piroxicam in the ApcMin mouse to evaluate the kinetics of NSAID-mediated tumor regression, the effects of genetic background and the incidence of resistance to chemoprevention. Starting at the time of weaning, C57Bl/6J-ApcMin mice were fed either the control diet (AIN-93G) or AIN-93G plus 200 p.p.m. piroxicam. Tumor multiplicity was significantly reduced in ApcMin mice that were fed 200 p.p.m. piroxicam until 100 or 200 days of age (94.4 and 95.7% reduction in tumor number, respectively; P < 0.001 versus AIN-93G controls). When the administration of piroxicam was delayed until 100 days of age and the mice were killed at 200 days of age, tumor multiplicity was reduced by 96.2% (P < 0.001 versus controls). Alternatively, when the administration of piroxicam was suspended at 100 days of age and the mice were killed at 200 days of age, tumor multiplicity was reduced by 68.0% (P < 0.001 versus controls). Short-term drug treatment periods for ApcMin animals with established tumors revealed that the kinetics of piroxicam-induced tumor regression were rapid: >90% reduction in tumor multiplicity was observed after 1 week of treatment with 200 p.p.m. piroxicam. The distribution of residual tumors in piroxicam-treated mice suggests that tumors of the duodenum and colon were relatively resistant to chemosuppression. Treatment of interspecific hybrid ApcMin mice with 200 p.p.m. piroxicam revealed that there was a strain-related effect on chemosuppression, suggesting the existence of genetic elements which modulate NSAID chemosensitivity. Finally, whole-genome allelic loss studies showed that there were few unique chromosomal deletions in the NSAID-resistant tumors from F1 mice, implying that loss-of-function mutations secondary to Apc inactivation are not likely to account for the observed difference in chemoresistance.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Guillen-Ahlers, S. A. Buechler, M. A. Suckow, F. J. Castellino, and V. A. Ploplis Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice Carcinogenesis, July 1, 2008; 29(7): 1421 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice PNAS, June 19, 2007; 104(25): 10625 - 10630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tomita, Y. Yamada, T. Oyama, K. Hata, Y. Hirose, A. Hara, T. Kunisada, Y. Sugiyama, Y. Adachi, H. Linhart, et al. Development of Gastric Tumors in ApcMin/+ Mice by the Activation of the {beta}-Catenin/Tcf Signaling Pathway Cancer Res., May 1, 2007; 67(9): 4079 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Simmons, R. M. Botting, and T. Hla Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Corpet and F. Pierre Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Huerta, J. R. Arteaga, R. W. Irwin, T. Ikezoe, D. Heber, and H. P. Koeffler PC-SPES Inhibits Colon Cancer Growth in Vitro and in Vivo Cancer Res., September 15, 2002; 62(18): 5204 - 5209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Hansen-Petrik, M. F. McEntee, B. Jull, H. Shi, M. B. Zemel, and J. Whelan Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice Cancer Res., January 1, 2002; 62(2): 403 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Andreassen, R. Vikse, I.-L. Steffensen, J. E. Paulsen, and J. Alexander Intestinal tumours induced by the food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in multiple intestinal neoplasia mice have truncation mutations as well as loss of the wild-type Apc+ allele Mutagenesis, July 1, 2001; 16(4): 309 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Hong, J. C. Bonventre, E. O'Leary, J. V. Bonventre, and E. S. Lander Deletion of cytosolic phospholipase A2 suppresses ApcMin-induced tumorigenesis PNAS, March 7, 2001; (2001) 51635898. [Abstract] [Full Text]
|
|
|
|
|
|
W. R. Bruce, A. Giacca, and A. Medline Possible Mechanisms Relating Diet and Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1271 - 1279. [Abstract] [Full Text]
|
|
|
|
|
|
J. Song, A. Medline, J. B. Mason, S. Gallinger, and Y.-I. Kim Effects of Dietary Folate on Intestinal Tumorigenesis in the ApcMin Mouse Cancer Res., October 1, 2000; 60(19): 5434 - 5440. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. B. H. Petrik, M. F. McEntee, B. T. Johnson, M. G. Obukowicz, and J. Whelan Highly Unsaturated (n-3) Fatty Acids, but Not {alpha}-Linolenic, Conjugated Linoleic or {gamma}-Linolenic Acids, Reduce Tumorigenesis in ApcMin/+ Mice J. Nutr., October 1, 2000; 130(10): 2434 - 2443. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Ritland, S. J. Gendler, L. J. Burgart, D. W. Fry, J. M. Nelson, A. J. Bridges, L. Andress, and W. E. Karnes Jr. Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase Fails to Suppress Adenoma Formation in ApcMin Mice but Induces Duodenal Injury Cancer Res., September 1, 2000; 60(17): 4678 - 4681. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. H. Goss and J. Groden Biology of the Adenomatous Polyposis Coli Tumor Suppressor J. Clin. Oncol., May 9, 2000; 18(9): 1967 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. H. Petrik, M. F. McEntee, C.-H. Chiu, and J. Whelan Antagonism of Arachidonic Acid Is Linked to the Antitumorigenic Effect of Dietary Eicosapentaenoic Acid in ApcMin/+ Mice J. Nutr., May 1, 2000; 130(5): 1153 - 1158. [Abstract] [Full Text]
|
|
|
|
|
|
K. H. Hong, J. C. Bonventre, E. O'Leary, J. V. Bonventre, and E. S. Lander Deletion of cytosolic phospholipase A2 suppresses ApcMin-induced tumorigenesis PNAS, March 27, 2001; 98(7): 3935 - 3939. [Abstract] [Full Text] [PDF]
|
|